PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Revolutionary technology will further boost OneSource’s scientific services offerings
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
A single-cell analysis solution that revolutionizes efficiency in drug discovery research by automating the collection of specific cells and intracellular components
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
The approval was driven by data from the Phase III TULIP-SC trial
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Subscribe To Our Newsletter & Stay Updated
